Ricks RC, Fry SA, eds. The Medical Basis for Radiation Accident Preparedness II: Experience and Follow-up since 1979. New York: Elsevier; 1990.. Ricks RC, Fry SA The Medical Basis for Radiation Accident Preparedness II: Experience and Follow-up since 1979. New York Elsevier1990.
Browne D, Weiss JF, MacVittie TJ, eds. Treatment of Radiation Injuries. New York: Plenum Pr; 1990.. Browne D, Weiss JF, MacVittie TJ Treatment of Radiation Injuries. New York Plenum Pr1990.
Fliedner TM, Cronkite EP, Bond VP, eds. Assessment of Radiation Effects by Molecular and Cellular Approaches. Dayton, OH: Alpha Med Pr; 1995.. Fliedner TM, Cronkite EP, Bond VP Assessment of Radiation Effects by Molecular and Cellular Approaches. Dayton, OH Alpha Med Pr1995.
MacVittie TJ, Weiss JF, Browne ED, eds. Proceedings of Advances in the Treatment of Radiation Injuries. Tarrytown, NY: Pergamon, Elsevier Sciences; 1996.. MacVittie TJ, Weiss JF, Browne ED Proceedings of Advances in the Treatment of Radiation Injuries. Tarrytown, NY Pergamon, Elsevier Sciences1996.
Karaoglou A, Desmet G, Kelly GN, Menzel HG, eds. The Radiological Consequences of the Chernobyl Accident. Luxembourg: Office for Official Publications of the European Communities; 1996.. Karaoglou A, Desmet G, Kelly GN, Menzel HG The Radiological Consequences of the Chernobyl Accident. Luxembourg Office for Official Publications of the European Communities1996.
Dainiak N, Schull WJ, Karkanitsa L, Aleinikova OA, eds. Radiation Injury and the Chernobyl Catastrophe. Miamisburg, OH: Alpha Med Pr; 1997.. Dainiak N, Schull WJ, Karkanitsa L, Aleinikova OA Radiation Injury and the Chernobyl Catastrophe. Miamisburg, OH Alpha Med Pr1997.
Ricks RC, Berger ME, O'Hara F, eds. The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victim. New York: Parthenon; 2002.. Ricks RC, Berger ME, O'Hara F The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victim. New York Parthenon2002.
Fliedner TM, Meineke V, Dainiak N, Gourmelon P, Akashi M, eds. Radiation-Induced Multi-Organ Involvement and Failure: A Challenge for Pathogenetic, Diagnostic and Therapeutic Approaches and Research. London: British Institute of Radiology; 2004.. Fliedner TM, Meineke V, Dainiak N, Gourmelon P, Akashi M Radiation-Induced Multi-Organ Involvement and Failure: A Challenge for Pathogenetic, Diagnostic and Therapeutic Approaches and Research. London British Institute of Radiology2004.
Schuening FG, Storb R, Goehle S, Graham TC, Appelbaum FR, Hackman R, et al..
Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. Blood. 1989;74:1308.-13 PubMed
Farese AM, Casey DB, Vigneulle RM, Siegel NR, Finn RF, Klover JA, et al..
A single dose of pegylated leridistim significantly improves neutrophil recovery in sublethally irradiated rhesus macaques. Stem Cells. 2001;19:514.-21 PubMedCrossRef
MacVittie TJ, Monroy R, Vigneulle RM, Zeman GH, Jackson WE.
The relative biological effectiveness of mixed fission-neutron-gamma radiation on the hematopoietic syndrome in the canine: effect of therapy on survival. Radiat Res. 1991;128:S29.-36 PubMed
MacVittie TJ, Monroy RL, Patchen ML, Souza LM.
Therapeutic use of recombinant human G-CSF (rhG-CSF) in a canine model of sublethal and lethal whole-body irradiation. Int J Radiat Biol. 1990;57:723.-36 PubMed
Schuening FG, Appelbaum FR, Deeg HJ, Sullivan-Pepe M, Graham TC, Hackman R, et al..
Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. Blood. 1993;81:20.-6 PubMed
Mettler FA Jr, Voelz GL.
Major radiation exposure—what to expect and how to respond. N Engl J Med. 2002;346:1554.-61 PubMed
Yehezkelli U, Dushnitsky T, Hourvitz A. Radiation terrorism: the medical challenge. Israeli Medical Association Journal. 2002;4:530.-4
Medical Management of Radiological Casualties—Handbook. 2nd ed. Bethesda: Armed Forces Radiology Research Institute; 2003.. Medical Management of Radiological Casualties—Handbook. 2nd ed. Bethesda Armed Forces Radiology Research Institute2003.
Meineke V, van Beuningen D, Sohns T, Fliedner TM.
Medical management principles for radiation accidents. Mil Med. 2003;168:219.-22 PubMed
Shigematsu I, Kamada N, Akiyama M, Sasaki H, eds. A-Bomb Radiation Effects Digest. Tokyo: Bunkodo/Chur: Harwood Academic; 1993.. Shigematsu I, Kamada N, Akiyama M, Sasaki H A-Bomb Radiation Effects Digest. Tokyo: Bunkodo/Chur Harwood Academic1993.
Schull WJ. Effects of Atomic Radiation: A Half-Century of Studies from Hiroshima and Nagasaki. New York J Wiley1996.
Anno GH, Young RW, Bloom RM, Mercier JR.
Dose response relationships for acute ionizing-radiation lethality. Health Phys. 2003;84:565.-75 PubMed
Walker RI, Cerveny RJ, eds.
Medical Consequences of Nuclear Warfare. Falls Church, VA: Office of the Surgeon General; 1989. Available athttp://www.afrri.usuhs.mil
Management of Terrorist Events Involving Radioactive Material. NCRP Report No. 138. Bethesda, MD: National Council on Radiation Protection and Measurements; 2001:125-34.. Management of Terrorist Events Involving Radioactive Material. NCRP Report No. 138. Bethesda, MD National Council on Radiation Protection and Measurements2001;125.-34
Hematologic consequences of exposure to ionizing radiation. Exp Hematol. 2002;30:513.-28 PubMed
Mettler FA Jr, Upton AC, eds. Medical Effects of Ionizing Radiation. 2nd ed. Philadelphia: WB Saunders; 1995.. Mettler FA Jr, Upton AC Medical Effects of Ionizing Radiation. 2nd ed. Philadelphia WB Saunders1995.
Hall EJ. Acute effects of total-body irradiation. Hall EJ Radiobiology for the Radiologist. 5th ed. Philadelphia Lippincott Williams & Wilkins2000;124.-35
van Bekkum DW.
Radiation sensitivity of the hemopoietic stem cell. Radiat Res. 1991;128:S4.-8 PubMed
Inoue T, Hirabayashi Y, Mitsui H, Sasaki H, Cronkite EP, Bullis JE Jr, et al..
Survival of spleen colony-forming units (CFU-S) of irradiated bone marrow cells in mice: evidence for the existence of a radioresistant subfraction. Exp Hematol. 1995;23:1296.-300 PubMed
Vorobiev AI. Acute radiation disease and biological dosimetry in 1993. Dainiak N, Schull WJ, Karkanitsa L, Aleinikova OA Radiation Injury and the Chernobyl Catastrophe. Miamisburg, OH Alpha Med Pr1997.
Goans RE, Holloway EC, Berger ME, Ricks RC.
Early dose assessment following severe radiation accidents. Health Phys. 1997;72:513.-8 PubMed
Baranov AE, Guskova AK, Nadejina NM, Nugis VY.
Chernobyl experience: biological indicators of exposure to ionizing radiation. Stem Cells. 1995;13:Suppl 169.-77 PubMed
T lymphocytes and immunosuppression in the burned patient: a review. Burns. 1994;20:487.-90 PubMed
Maldonado MD, Venturoli A, Franco A, Nunez-Roldan A.
Specific changes in peripheral blood lymphocyte phenotype from burn patients. Probable origin of the thermal injury-related lymphocytopenia. Burns. 1991;17:188.-92 PubMed
Mistry S, Mistry NP, Arora S, Antia NH.
Cellular immune response following thermal injury in human patients. Burns Incl Therm Inj. 1986;12:318.-24 PubMed
Cheadle WG, Pemberton RM, Robinson D, Livingston DH, Rodriguez JL, Polk HC Jr.
Lymphocyte subset responses to trauma and sepsis. J Trauma. 1993;35:844.-9 PubMed
Dainiak N, Sorba S. Early identification of radiation accident victims for therapy of bone marrow failure. Dainiak N, Schull WJ, Karkanitsa L, Aleinikova OA Radiation Injury and the Chernobyl Catastrophe. Miamisburg, OH Alpha Med Pr1997.
Barabanova AV. Acute radiation syndrome with cutaneous syndrome. Ricks RC, Berger ME, O'Hara FM The Medical Basis for Radiation Accident Preparedness: The Clinical Care of Victims. New York Parthenon2002;217.-24
Peter RU. Management of skin injuries in radiation accidents: the cutaneous radiation syndrome. Ricks RC, Berger ME, O'Hara FM The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victims. New York Parthenon2002;225.-9
Fliedner TM, Friesecke I, Beyrer K. Medical Management of Radiation Accidents: Manual on the Acute Radiation Syndrome. Oxford British Institute of Radiology2001.
Management of Terrorist Events Involving Radioactive Material. NCRP Publication No. 138. Bethesda, MD: National Council on Radiation Protection and Measurements; 2001:54-73.. Management of Terrorist Events Involving Radioactive Material. NCRP Publication No. 138. Bethesda, MD National Council on Radiation Protection and Measurements2001;54.-73
Fullerton CS, Urano RJ. The other side of chaos: understanding the patterns of post-traumatic responses. Fullerton CS, Ursano RJ Post-traumatic Stress Disorder: Acute and Long-Term Responses to Trauma and Disaster. Washington, DC American Psychiatric Pr1997;3.-18
DiGiovanni C Jr.
Domestic terrorism with chemical or biological agents: psychiatric aspects. Am J Psychiatry. 1999;156:1500.-5 PubMed
Pynoos RS, Goenjian AK, Steinberg AM.
A public mental health approach to the postdisaster treatment of children and adolescents. Child Adolesc Psychiatr Clin N Am. 1998;7:195.-210, x PubMed
Institute of Medicine/National Research Council. Potential Radiation Exposure in Military Operations: Protecting the Soldier Before, During and After. Committee on Battlefield Radiation Exposure Criteria. Washington, DC: National Academy Pr; 1999.Institute of Medicine/National Research Council.. Potential Radiation Exposure in Military Operations: Protecting the Soldier Before, During and After. Committee on Battlefield Radiation Exposure Criteria. Washington, DC National Academy Pr1999.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Pr; 1994.American Psychiatric Association.. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC American Psychiatric Pr1994.
Sine RC, Levine IH, Jackson WE, Hawley AL, Prasanna PG, Grace MB, et al..
Biodosimety Assessment Tool: a post-exposure software application for management of radiation accidents. Mil Med. 2001;166:85.-7 PubMed
Goans RE, Holloway EC, Berger ME, Ricks RC.
Early dose assessment in criticality accidents. Health Phys. 2001;81:446.-9 PubMed
Bender MA, Gooch PC.
Somatic chromosome aberrations induced by human whole-body irradiation: the “Recuplex” criticality accident. Radiat Res. 1966;29:568.-82 PubMed
Voisin P, Barquinero F, Blakely B, Lindholm C, Lloyd D, Luccioni C, et al..
Towards a standardization of biological dosimetry by cytogenetics. Cell Mol Biol (Noisy-le-grand). 2002;48:501.-4 PubMed
Voisin P, Benderitter M, Claraz M, Chambrette V, Sorokine-Durm I, Delbos M, et al..
The cytogenetic dosimetry of recent accidental overexposure. Cell Mol Biol (Noisy-le-grand). 2001;47:557.-64 PubMed
Prasanna PG, Subramanian U, Greenhill RG, Loats H, Jacocks JM, Jackson WE, et al.. Cytogenetic biodosimetry strategy for potential radiation mass casualties. The Health Physics Society Midyear Topical Meeting on Homeland Defense and Emergency Response. 36th HPS Topical Meeting. Washington, DC Health Physics Society2003;218.-23
Durante M, George K, Yang TC.
Biological dosimetry by interphase chromosome painting. Radiat Res. 1996;145:53.-60 PubMed
Kanda R, Hayata I, Lloyd DC.
Easy biodosimetry for high-dose radiation exposures using drug-induced, prematurely condensed chromosomes. Int J Radiat Biol. 1999;75:441.-6 PubMed
Prasanna PG, Escalada ND, Blakely WF.
Induction of premature chromosome condensation by a phosphatase inhibitor and a protein kinase in unstimulated human peripheral blood lymphocytes: a simple and rapid technique to study chromosome aberrations using specific whole-chromosome DNA hybridization probes for biological dosimetry. Mutat Res. 2000;466:131.-41 PubMed
Amundson SA, Do KT, Shahab S, Bittner M, Meltzer P, Trent J, et al..
Identification of potential mRNA biomarkers in peripheral blood lymphocytes for human exposure to ionizing radiation. Radiat Res. 2000;154:342.-6 PubMed
Amundson SA, Fornace AJ Jr.
Gene expression profiles for monitoring radiation exposure. Radiat Prot Dosimetry. 2001;97:11.-6 PubMed
Schreyer SK, Karkanitsa LV, Albanese J, Ostapenko VA, Shevchuk VY, Dainiak N. Analysis of radiation-associated changes in gene expression using microarray technology. Br J Radiol. 2002;26:Suppl129.-39
Grace MB, McLeland CB, Blakely WF.
Real-time quantitative RT-PCR assay of GADD45 gene expression changes as a biomarker for radiation biodosimetry. Int J Radiat Biol. 2002;78:1011.-21 PubMed
Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N.
Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis. 1999;28:331.-40 PubMed
Weisbart RH, Golde DW, Clark SC, Wong GG, Gasson JC.
Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature. 1985;314:361.-3 PubMed
Weisbart RH, Gasson JC, Golde DW.
Colony-stimulating factors and host defense. Ann Intern Med. 1989;110:297.-303 PubMed
Arnaout MA, Wang EA, Clark SC, Sieff CA.
Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest. 1986;78:597.-601 PubMed
Cohen AM, Hines DK, Korach ES, Ratzkin BJ.
In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor. Infect Immun. 1988;56:2861.-5 PubMed
Gasson JC, Weisbart RH, Kaufman SE, Clark SC, Hewick RM, Wong GG, et al..
Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. Science. 1984;226:1339.-42 PubMed
Mayer P, Schutze E, Lam C, Kricek F, Liehl E.
Recombinant murine granulocyte-macrophage colony-stimulating factor augments neutrophil recovery and enhances resistance to infections in myelosuppressed mice. J Infect Dis. 1991;163:584.-90 PubMed
Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood. 1996;88:3675.-85 PubMed
Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, et al..
Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773.-8 PubMed
Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS.
Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol. 1995;13:1323.-7 PubMed
Ciernik IF, Schanz U, Gmur J.
Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant. 1999;24:147.-51 PubMed
Demirer T, Ayli M, Dagli M, Haznedar R, Genc Y, Fen T, et al..
Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol. 2002;118:1104.-11 PubMed
Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H, et al..
A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant. 1998;22:965.-9 PubMed
Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, et al..
Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA. 2003;289:1941.-9 PubMed
Immunomodulation and blood transfusion. Am J Ther. 2002;9:389.-95 PubMed
The cytomegalovirus-“safe” blood product: is leukoreduction equivalent to antibody screening? Transfus Med Rev. 2000;14:112.-36 PubMed
Narvios AB, Lichtiger B.
Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. Haematologica. 2001;86:749.-52 PubMed
Jammet HP, Mathé G, Pendic B, Duplan JF, Maupin B, Latarjet R, et al.. Étude de six cas d'irradiation totale aiguë accidentelle. Rev Fr Etud Clin Biol. 1959;4:210.-25
Mathé G, Jammet H, Pendic B, Schwarzenberg L, Duplan JF, Maupin B, et al.. Transfusions et greffes de moelle osseuse homologue chez des humains irradiés a haute dose accidentellement. Rev Fr Etud Clin Biol. 1959;4:226.-38
Maekawa K. Overview of medical care for highly exposed victims in the Tokaimura accident. Ricks RC, Berger ME, O'Hara FM The Medical Basis for Radiation Accident Preparedness: The Clinical Care of Victims. New York Parthenon2002;313.-8
Densow D, Kindler H, Baranov AE, Tibken B, Hofer EP, Fliedner TM. Criteria for the selection of radiation accident victims for stem cell transplantation. Dainiak N, Schull WJ, Karkanitsa L, Aleinikova OA Radiation Injury and the Chernobyl Catastrophe. Miamisburg, OH Alpha Med Pr1997.
Baranov A, Gale RP, Guskova A, Piatkin E, Selidovkin G, Muravyova L, et al..
Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med. 1989;321:205.-12 PubMed
Fliedner TM, Graessle D, Reimers K, Weis M, Paulsen C. Stem cell transplantation in radiation accidents. Medical Aspects of Radiation Emergency: The Criticality Accident in Tokaimura. Chiba, Japan National Institute of Radiological Sciences2000;228.-35
Bagdasarov AA, Raushenbakh MO, Abdulaev GM, Beliaeva BF, Lagutina NI.
[Treatment of acute radiation sickness by thrombocytic mass]. Probl Gematol Pereliv Krovi. 1959;4:3.-7 PubMed
Furth FW, Coulter MP, Miller RW, Howland JW, Swisher SN.
The treatment of the acute radiation syndrome in dogs with aureomycin and whole blood. J Lab Clin Med. 1953;41:918.-28 PubMed
Jackson DP, Sorensen DK, Cronkite EP, Bond VP, Fliedner TM.
Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia. J Clin Invest. 1959;38:1689.-97 PubMed
Perman V, Cronkite EP, Bond VP, Sorensen DK.
The regenerative ability of hemopoietic tissue following lethal x-irradiation in dogs. Blood. 1962;19:724.-37 PubMed
Sorensen DK, Bond VP, Cronkite EP, Perman V. An effective therapeutic regimen for the hemopoietic phase of the acute radiation syndrome in dogs. Radiat Res. 1960;13:669.-85
Kumar KS, Srinivasan V, Toles RE, Miner VL, Jackson WE, Seed TM.
High-dose antibiotic therapy is superior to a 3-drug combination of prostanoids and lipid A derivative in protecting irradiated canines. J Radiat Res (Tokyo). 2002;43:361.-70 PubMed
Engels EA, Ellis CA, Supran SE, Schmid CH, Barza M, Schenkein DP, et al..
Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis. 1999;28:256.-66 PubMed
Engels EA, Lau J, Barza M.
Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998;16:1179.-87 PubMed
Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D.
Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer—is it justified? [Letter]. Clin Infect Dis. 1997;25:346.-8 PubMed
Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Gomez C, Perea S, et al..
Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants. Antimicrob Agents Chemother. 1997;41:1175.-7 PubMed
Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al..
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730.-51 PubMed
Hughes WT. Use of antimicrobial agents for treatment of infection in the neutropenic immunocompromised patient. Ricks RC, Berger ME, O'Hara FM The Medical Basis for Radiation-Accident Preparedness. The Clinical Care of Victims. Washington, DC Parthenon2002;117.-29
Hughes WT, Armstrong D, Bodey GP, Brown AE, Edwards JE, Feld R, et al..
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997;25:551.-73 PubMed
Brook I, Elliott TB, Ledney GD, Knudson GB.
Management of postirradiation sepsis. Mil Med. 2002;167:105.-6 PubMed
Goans RE. Clinical care of the radiation-accident patient: patient presentation, assessment, and initial diagnosis. Ricks RC, Berger ME, O'Hara FM The Medical Basis for Radiation-Accident Preparedness: The Clinical Care of Victims. Washington, DC Parthenon2002;11.-22
Abbott B, Ippoliti C, Bruton J, Neumann J, Whaley R, Champlin R.
Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant. 1999;23:265.-9 PubMed
Serotonergic mediation of vomiting. J Pediatr Gastroenterol Nutr. 1995;21:Suppl 1S22.-8 PubMed
Clinical studies with ondansetron in the control of radiation-induced emesis. Eur J Cancer Clin Oncol. 1989;25:Suppl 1S29.-33 PubMed
Priestman TJ, Roberts JT, Upadhyaya BK.
A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol R Coll Radiol. 1993;5:358.-63 PubMed
Farese AM, Williams DE, Seiler FR, MacVittie TJ.
Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia. Blood. 1993;82:3012.-8 PubMed
Farese AM, Hunt P, Grab LB, MacVittie TJ.
Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest. 1996;97:2145.-51 PubMed
Farese AM, Casey DB, Smith WG, Vigneulle RM, McKearn JP, MacVittie TJ.
Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells. 2001;19:522.-33 PubMed
MacVittie TJ, Farese AM, Herodin F, Grab LB, Baum CM, McKearn JP.
Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor. Blood. 1996;87:4129.-35 PubMed
Neelis KJ, Dubbelman YD, Qingliang L, Thomas GR, Eaton DL, Wagemaker G.
Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Exp Hematol. 1997;25:1084.-93 PubMed
Neelis KJ, Hartong SC, Egeland T, Thomas GR, Eaton DL, Wagemaker G.
The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. Blood. 1997;90:2565.-73 PubMed
Pegfilgrastim for chemotherapy-induced neutropenia. Clin J Oncol Nurs. 2003;7:55.-6, 63-4 PubMed
Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, et al..
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20:727.-31 PubMed
Farese AM, Roskos L, Stead RB, MacVittie TJ. r-metHuG-CSF-SD/01 (SD/01) significantly improves neutrophil recovery in myelosuppressed non human primates [Abstract]. Blood. 1999;94:49a.
Brook I, Ledney GD.
Effect of antimicrobial therapy on the gastrointestinal bacterial flora, infection and mortality in mice exposed to different doses of irradiation. J Antimicrob Chemother. 1994;33:63.-72 PubMed
Brook I, Ledney GD.
Quinolone therapy in the prevention of endogenous and exogenous infection after irradiation. J Antimicrob Chemother. 1994;33:777.-84 PubMed
Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. JAMA. 1994;272:1183-9. [PMID: 7933348].
Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. JAMA. 1994;272:1183.-9 PubMed
Brook I, Elliott TB, Ledney GD.
Quinolone therapy of Klebsiella pneumoniae
sepsis following irradiation: comparison of pefloxacin, ciprofloxacin, and ofloxacin. Radiat Res. 1990;122:215.-7 PubMed
Epstein JB, Gorsky M, Hancock P, Peters N, Sherlock CH.
The prevalence of herpes simplex virus shedding and infection in the oral cavity of seropositive patients undergoing head and neck radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;94:712.-6 PubMed
Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monogr. 1990;103.-5 PubMed
Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al..
Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545.-52 PubMed
Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al..
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845.-51 PubMed
Schaffner A, Schaffner M.
Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis. 1995;172:1035.-41 PubMed
Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, et al..
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med. 1993;118:495.-503 PubMed
Kazakov VS, Demidchik EP, Astakhova LN.
Thyroid cancer after Chernobyl [Letter]. Nature. 1992;359:21. PubMed
Guidance: Potassium iodide as a thyroid blocking agent in radiation emergencies. U.S. Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research. December 2001. Available athttp://www.fda.gov/cder/guidance/4825fnl.pdf